- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BAY 59-7939 | Xarelto®
rivaroxaban is an approved drug (EMA (2008), FDA (2011))
Compound class: Synthetic organic
Comment: First in class orally active direct factor Xa inhibitor.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: rivaroxaban
1. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K et al.. (2018)
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Lancet, 391 (10117): 219-229. [PMID:29132880]
2. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M et al.. (2017)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.
Can J Cardiol, 33 (8): 1027-1035. [PMID:28754388]
3. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB et al.. (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Nat Med, 19 (4): 446-51. [PMID:23455714]
4. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. (2005)
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
J Thromb Haemost, 3 (3): 514-21. [PMID:15748242]